Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Alimentary Pharmacology & Therapeutics|2015Cited by 266
Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s DiseaseMaria Rosario, Irving H. Fox, Bruce E. Sands et al.|Journal of Crohn s and Colitis|2017Cited by 161
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Clinical Pharmacokinetics|2017Cited by 158
Corrigendum: Exposure—efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s DiseaseMaria Rosario, Irving H. Fox, Jonathan French et al.|Journal of Crohn s and Colitis|2018Cited by 122
P385 Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's diseaseM. Rosario, A. Milton, Nathanael L. Dirks et al.|Journal of Crohn s and Colitis|2014Cited by 6